此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

克拉屈滨、伊达比星、阿糖胞苷和维奈托克治疗急性髓性白血病、高危骨髓增生异常综合征或急变期慢性髓性白血病患者

2026年11月10日 更新者:M.D. Anderson Cancer Center

克拉屈滨加伊达比星加阿糖胞苷 (ARAC) 治疗 AML、HR MDS 或 CML 成髓细胞期患者的 II 期研究

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

研究概览

详细说明

Primary Objectives:

I. To determine the complete response rate (CR) of cladribine in combination with idarubicin and cytarabine (araC) in patients with acute myeloid leukemia (AML), high risk (HR) myelodysplastic syndrome (MDS), or myeloid blast phase of chronic myeloid leukemia (CML).

Secondary Objectives:

I. To determine the overall response rate (ORR) of cladribine in combination with idarubicin and araC in patients with AML, HR MDS, or myeloid blast phase of CML.

II. To assess overall survival (OS) and event free survival (EFS) of patients treated with cladribine, idarubicin, and araC (cytarabine).

III. To assess the duration of response to the combination in patients with AML, HR MDS, or myeloid blast phase of CML.

IV. To determine the safety and tolerability of the combination in patients with AML, HR MDS, or myeloid blast phase of CML.

Exploratory Objectives:

I. To study and describe the relationship between pretreatment patient/disease characteristics (including AML-associated molecular abnormalities) and outcome.

II. To identify molecular biomarkers predictive of response to therapy.

III. To study and describe the relationship between patient/disease characteristics, use of intrathecal prophylaxis, and incidence of leptomeningeal disease.

IV. To study the trajectories of leukemia mutations and molecular minimal residual disease (MRD) during the therapy.

OUTLINE:

INDUCTION: Patients receive cladribine intravenously (IV) and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax orally (PO) on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO twice daily (BID) on days 6-19 or gilteritinib PO once daily (QD) on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6-12 months.

研究类型

介入性

注册 (估计的)

508

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • M D Anderson Cancer Center
        • 接触:
          • Tapan M. Kadia
          • 电话号码:713-792-7305
        • 首席研究员:
          • Tapan M. Kadia

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients with a diagnosis of AML, Acute Biphenotypic Leukemia, or high risk MDS (>/= 10% blasts or IPSS >/= intermediate-2) will be eligible. Patients with CML in Myeloid Blast Phase are also eligible.

  2. For Frontline cohort (1 or 4): No prior potentially-curative therapy for leukemia. Prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, decitabine, ATRA, or a total dose of cytarabine up to 2g (for emergency use for stabilization) is allowed. Patients deemed able to receive venetoclax (ie. insurance clearance) will be assigned to Frontline cohort 4. Patients with secondary AMLwho have been treated for their antecedent myeloid neoplasm will be enrolled into the separate Secondary AML cohort.

  3. For Salvage cohort: Patients with previously treated, relapsed or refractory AML, Acute Biphenotypic Leukemia, or CML in Myeloid Blast Phase are eligible.

  4. Age </= 65 years.

  5. Adequate organ function as defined below:

    • liver function (bilirubin < 2mg/dL, AST and/or ALT <3 x ULN - or <5 x ULN if related to leukemic involvement)
    • kidney function (creatinine < 1.5 x ULN ).
    • known cardiac ejection fraction of > or = 45% within the past 6 months
  6. ECOG performance status of ≤ 2.

  7. A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.

  8. Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient is required prior to their enrollment on the protocol.

Exclusion Criteria:

  1. Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.
  2. Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  3. Patient with documented hypersensitivity to any of the components of the chemotherapy program.
  4. Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (cladribine, cytarabine, idarubicin)

INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.

Correlative studies

Given IV

其他名称:
  • .beta.-阿糖胞苷
  • 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-.beta.-D-阿拉伯呋喃糖基胞嘧啶
  • 1-β-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-β-D-阿拉伯呋喃糖基胞嘧啶
  • 1.beta.-D-阿拉伯呋喃糖基胞嘧啶
  • 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
  • 亚历山大
  • 阿糖胞苷C
  • ARA细胞
  • 阿拉伯语
  • 阿拉伯呋喃糖基胞嘧啶
  • 阿糖基胞嘧啶
  • 阿糖胞苷
  • 阿拉伯胞苷
  • 阿胞苷
  • CHX-3311
  • 赛塔贝尔
  • Cytosar
  • 胞嘧啶阿拉伯糖苷
  • 胞嘧啶-.beta.-阿拉伯糖苷
  • 胞嘧啶-β-阿拉伯糖苷
  • 艾帕法
  • 斯塔拉西德
  • 他拉宾 PFS
  • U 19920
  • U-19920
  • 乌迪西尔
  • WR-28453
  • Β-胞嘧啶阿拉伯糖苷

Given IV

其他名称:
  • 4-去甲氧基道诺霉素
  • 4-去甲氧基柔红霉素
  • 4-DMDR

Given IV

其他名称:
  • 2-CDA
  • CdA
  • 2CDA
  • 克拉德里比纳
  • 勒乌斯塔
  • 来司他丁
  • 左司他汀
  • RWJ-26251

Given PO

其他名称:
  • 文克莱斯特
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • 文克利托

Given PO

其他名称:
  • ASP2215
  • Xospata
  • ASP-2215

Given PO

其他名称:
  • 利达普
  • PKC412
  • CGP 41251
  • CGP41251
  • N-苯甲酰星形孢菌素
  • N-苯甲酰星孢菌素
  • PKC-412

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Complete response (CR) rate
大体时间:Up to 12 months

CR rate will be determined.

Up to 12 months

次要结果测量

结果测量
措施说明
大体时间
Overall response rate (ORR)
大体时间:Up to 12 months

ORR will be determined.

Up to 12 months
Overall survival (OS)
大体时间:Up to 12 months

OS will be assessed.

Up to 12 months
Event-free survival (EFS)
大体时间:Up to 12 months

EFS will be assessed.

Up to 12 months
Duration of response
大体时间:Up to 12 months

Duration of response will be assessed.

Up to 12 months
Incidence of toxicities
大体时间:Up to 12 months

Safety and tolerability of cladribine in combination with idarubicin and cytarabine will be determined.

Up to 12 months

其他结果措施

结果测量
措施说明
大体时间
Use of intrathecal prophylaxis
大体时间:Up to 12 months

The relationship between patient/disease characteristics and use of intrathecal prophylaxis will be studied and described.

Up to 12 months
Incidence of leptomeningeal disease
大体时间:Up to 12 months

The relationship between patient/disease characteristics and incidence of leptomeningeal disease will be studied and described.

Up to 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Tapan M Kadia、M.D. Anderson Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年5月19日

初级完成 (估计的)

2030年5月31日

研究完成 (估计的)

2030年5月31日

研究注册日期

首次提交

2014年4月14日

首先提交符合 QC 标准的

2014年4月14日

首次发布 (估计的)

2014年4月16日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅